Myriad's Impact on Gene Patents
Nature Biotechnology, Vol. 34, No. 11, p. 1119-1123, Nov. 2016
University of Cambridge Faculty of Law Research Paper No. 58/2017
8 Pages Posted: 4 Aug 2017 Last revised: 25 Jun 2019
Date Written: November 8, 2016
Abstract
In the three years since the US Supreme Court’s decision in AMP v Myriad, there has been much debate and speculation about the impact of the Myriad case on the biotech industry, particularly on the status of gene patents. Was it a significant decision or, as Lord Tennyson might have argued, just another decision in a myriad of single instances that make up a confused and confusing law of patents?
Keywords: Patents, BRCA, Myriad, Gene Patents, Patent Publications, Empirical Analysis
JEL Classification: O3, O30, O31, O32, O33, O34
Suggested Citation: Suggested Citation
Here is the Coronavirus
related research on SSRN
